Medscape Conference Coverage, based on selected sessions at the:

American Association for Cancer Research (AACR) 2008 Annual Meeting

April 12 - 16, 2008; San Diego, California

This activity is not sanctioned by, nor a part of, the American Association for Cancer Research.
 

Conference News

  • Cediranib: Survival in Recurrent Glioblastoma

    Preliminary data show that treatment with the experimental compound cediranib improved both progression-free survival and overall survival in patients with recurrent glioblastoma who failed standard treatments.Medscape Medical News, April 28, 2008
  • Experimental Vaccine for Prostate Cancer

    A combination of GVAX immunotherapy with ipilimumab lowered prostate-specific antigen in the majority of patients who received the highest doses, and also reduced metasis to the bones and abdominal lymph nodes.Medscape Medical News, April 28, 2008
  • Dietary Lignans Improve Breast Cancer Survival

    A high intake of dietary lignans was found to improve survival in postmenopausal breast cancer patients, although no association was seen in premenopausal women.Medscape Medical News, April 25, 2008
  • ODC1 Gene Possible Target for Neuroblastoma

    The overexpression of ODC1 was shown to be associated with poor outcomes in childhood neuroblastoma and could represent an important therapeutic target.Medscape Medical News, April 24, 2008
  • Racial Disparities in Prostate and Breast Cancer

    Social, economic, and healthcare inequalities contribute to the disparities seen in patient outcomes among certain minorities, but genetic differences in tumor biology appear to play a role in both prostate and breast cancer.Medscape Medical News, April 23, 2008
  • Nanotechnology: Detection of Prostate Cancer

    Preliminary results show that the use of nanotechnology allowed for the detection of 6 biomarkers associated with prostate cancer, and might enhance the ability to diagnose the disease in its early state.Medscape Medical News, April 22, 2008
  • Prenatal Folic Acid Lowers Risk for Colon Cancer

    Supplementation with folic acid reduced the risk for colon cancer in the offspring of rats when given during the prenatal period, but it had no effect on young rats that were supplemented after birth.Medscape Medical News, April 18, 2008
  • Surgical Resection in Older Lung Cancer Patients

    Patients in their 80s with localized disease did as well as younger patients after surgical resection, and survival rates were shown to be similar.Medscape Medical News, April 17, 2008
  • Celecoxib Reduces Colon Adenomas

    Chemoprevention with celecoxib was shown to be highly effective in decreasing the incidence of colon adenomas, but was associated with cardiovascular risk in some patients.Medscape Medical News, April 16, 2008
  • Reducing the Recurrence of Colorectal Adenomas

    A combination of difluoromethylornithine at a low dose and the NSAID sulindac reduced the risk for recurrent colorectal adenomas by as much as 95%.Medscape Medical News, April 15, 2008
  • Vaccine for HER2-Overexpression Breast Cancer

    The HER2 E75 peptide vaccine was successful in reducing the risk for disease recurrence and in cutting the mortality rate by half; the effect was especially pronounced in women with low-expressing HER2-positive breast tumors.Medscape Medical News, April 15, 2008
  • Genes for Tamoxifen Resistance in Breast Cancer

    Seven genes that are responsible for tamoxifen resistance and tumor aggressiveness in estrogen-receptor-positive breast cancers have been identified.Medscape Medical News, April 14, 2008
  • Smoking Cessation, Diet, and Exercise

    Although more research is needed, especially randomized controlled trials, lifestyle factors and health habits might influence survival and cancer risk among cancer survivors.Medscape Medical News, April 13, 2008
Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Association for Cancer Research. These materials and the related activity are not sanctioned by the American Association for Cancer Research or the commercial supporter of the conference and do not constitute an official part of that conference.